
Ärztliche Leiterin des MVZ Endokrinologikum Göttingen
Arbeitsgruppenleiterin „Experimentelle und klinische Osteologie“, Klinik für Gastroenterologie, gastrointestinale Onkologie und Endokrinologie, UMG
www.endokrinologikum.com
https://gastroenterologie.umg.eu/forschung/working-groups/working-group-siggelkow/
Heide Siggelkow works as the medical director and endocrinologist in an outpatient clinic for endocrine or metabolic bone diseases including osteoporosis, hypoparathyroidism, hyperparathyroidism and rare bone diseases. Between 2011 and 2015, she was head of the Association of German Language Societies in the special Field of Osteology (DVO). In this position, she initiated and supported the development of the Osteologic Research Centers DVO. She has been president of the German Society of Osteology (DGO) from 2017–2019. In 2017, the Intensive Course for Clinical Endocrinology of the German Society of Endocrinology (DGE) took place in Göttingen under her leadership, and in 2019 she hosted the yearly German Congress of Endocrinology in Göttingen. From 2018-2022 she has been cofounder and spokesperson of the German network of rare bone diseases, “Netzwerk für seltene Osteopathien NetsOs”. 2017-2020 she was member of the European Calcified Tissue Society (ECTS) Website and Social Media Action Group, since 2021 she joined the ECTS Action group of Rare Bone Diseases and is member of the ECTS Board since 2022. 2020-2024 she was member of the ESE Education committee and representative in the PARAT programme of the European Society of Endocrinology (ESE). She is now Expert Panel member of the ESE Educational Programme on Rare Calcium, Phosphate and Bone Disorders (RCPBD). Her basic scientific work at the University of Göttingen Medical Center focuses on molecular and metabolic mechanisms important for the interplay between fat and bone in primary and secondary forms of osteoporosis, with a special focus on cortisol and bone. Another main topic is the investigation of mechanisms of osteoporosis in mastocytosis. Her clinical research is now concentrated on secondary forms of osteoporosis and on hypoparathyroidism with a special focus on quality of life.
MedF3 as a network was important for my own development and represents the opportunity for young women in leading positions at the University Medical Center or at the University of Göttingen to be supported and to be part of an engaged group of female basic and clinical researchers.